Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00112658
Recruitment Status : Unknown
Verified December 2006 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : June 3, 2005
Last Update Posted : May 20, 2011
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective as first-line therapy in treating pancreatic cancer.

PURPOSE: This randomized phase II/III trial is studying how well combination chemotherapy works as first-line therapy in treating patients with metastatic pancreatic cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: fluorouracil Drug: gemcitabine hydrochloride Drug: irinotecan hydrochloride Drug: leucovorin calcium Drug: oxaliplatin Phase 2 Phase 3

Detailed Description:



  • Compare the objective response rate in patients with metastatic adenocarcinoma of the pancreas treated with oxaliplatin, irinotecan, leucovorin calcium, and fluorouracil vs gemcitabine as first-line chemotherapy. (Phase II)
  • Compare the survival of patients treated with these regimens. (Phase III)


  • Compare the toxicity of these regimens in these patients.
  • Compare progression-free survival of patients treated with these regimens. (Phase III)
  • Compare the overall response rate in patients treated with these regimens. (Phase III)
  • Compare quality of life of patients treated with these regimens. (Phase III)

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oxaliplatin IV over 2 hours, irinotecan IV over 1½ hours, leucovorin calcium IV over 2 hours, and fluorouracil IV over 5 minutes on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days.
  • Arm II: Patients receive gemcitabine IV on days 1, 8, 15, 22, 29, 36, and 43. Beginning on day 57, patients receive gemcitabine IV once weekly for 3 weeks (days 57, 64, and 71). Courses repeat every 28 days.

PROJECTED ACCRUAL: A total of 348 patients (88 for phase II and 260 for phase III) will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 348 participants
Allocation: Randomized
Primary Purpose: Treatment
Official Title: Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients
Study Start Date : November 2004

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. Objective response rate (Phase II)
  2. Survival (Phase III)

Secondary Outcome Measures :
  1. Toxicity
  2. Progression-free survival (Phase III)
  3. Quality of life (Phase III)
  4. Overall response rate (Phase III)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed adenocarcinoma of the pancreas

    • No other pancreatic tumor type, including either of the following:

      • Neuroendocrine tumor
      • Acinar cell tumor
    • Metastatic disease
  • Measurable disease in an area not previously irradiated
  • No cerebral metastases or meningeal involvement of the tumor



  • 18 to 75

Performance status

  • WHO 0-1

Life expectancy

  • Not specified


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Bilirubin ≤ 1.5 times upper limit of normal (biliary drainage allowed)


  • Creatinine < 120 mmol/L


  • No prior myocardial infarction
  • No prior angina
  • No uncompensated cardiac or coronary insufficiency
  • No symptomatic arrhythmia


  • No prior inflammatory bowel disease
  • No prior chronic diarrhea
  • No unresolved symptomatic occlusion or subocclusion of the bowel


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No ongoing active infection
  • No other malignancy except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
  • No contraindication to study treatment
  • No other serious medical disorder that would preclude study treatment
  • No psychiatric disorder or social or geographic situation that would preclude study participation
  • Not detained or under the guardianship of another person


Biologic therapy

  • Not specified


  • No prior chemotherapy

Endocrine therapy

  • Not specified


  • No prior radiotherapy


  • Not specified


  • No concurrent participation in another clinical trial using therapeutic experimental agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00112658

  Hide Study Locations
Centre Hospitalier Universitaire d'Amiens
Amiens, France, 80054
Hopital Duffaut
Avignon, France, 84902
Centre Hospitalier General
Belfort, France, 90000
Centre Hospitalier Regional de Besancon - Hopital Jean Minjoz
Besancon, France, 25030
Hopital Avicenne
Bobigny, France, 93009
Hopital Saint Andre
Bordeaux, France, 33075
Institut Bergonie
Bordeaux, France, 33076
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France, 33300
Centre Hospitalier Docteur Duchenne
Boulogne Sur Mer, France, 62200
Hopital Ambroise Pare
Boulogne-Billancourt, France, F-92104
CHU de Caen
Caen, France, 14033
Centre Regional Francois Baclesse
Caen, France, 14076
Centre Jean Perrin
Clermont-Ferrand, France, 63011
CHR Clermont Ferrand, Hotel Dieu
Clermont-Ferrand, France, 63058
Hopitaux Civils de Colmar
Colmar, France, 68024
Centre Hospitalier Universitaire Henri Mondor
Creteil, France, 94000
Hopital Du Bocage
Dijon, France, 21034
Centre de Lutte Contre le Cancer Georges-Francois Leclerc
Dijon, France, 21079
Centre Hospitalier Intercommunal St. Aubin les Elbeuf
Elbeuf, France, 76503
Clinique Saint Vincent
Epernay, France, 51200
Centre Hospitalier Departemental
La Roche Sur Yon, France, F-85025
CMC Les Ormeaux
Le Havre, France, 76600
Centre Oscar Lambret
Lille, France, 59020
Hopital Saint Vincent de Paul
Lille, France, F-59020
Polyclinique des Quatre Pavillons
Lormont, France, 33310
Hopital de la Croix Rousse
Lyon, France, 69317
Centre Leon Berard
Lyon, France, 69373
Hopital Edouard Herriot - Lyon
Lyon, France, 69437
Hopital Ambroise Pare
Marseille, France, 13291
CHU de la Timone
Marseille, France, 13385
CHU Nord
Marseille, France, 13915
Hopital Notre-Dame de Bon Secours
Metz, France, 57038
Centre Hospitalier General de Mont de Marsan
Mont-de-Marsan, France, 40000
Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
Montpellier, France, 34298
Centre Regional Rene Gauducheau
Nantes-Saint Herblain, France, 44805
CHR D'Orleans - Hopital de la Source
Orleans, France, 45067
Hopital Bichat - Claude Bernard
Paris, France, 75018
Hopital Saint Michel
Paris, France, 75674
Centre Hospitalier de Perpignan
Perpignan, France, 66046
Centre Hospitalier Lyon Sud
Pierre Benite, France, 69495
Institut Jean Godinot
Reims, France, 51056
CHU - Robert Debre
Reims, France, 51092
Centre Eugene Marquis
Rennes, France, 35064
Hopital Charles Nicolle
Rouen, France, 76031
Clinique Armoricaine De Radiologie
Saint Brieuc, France, F-22015
Centre Rene Huguenin
Saint Cloud, France, 92210
Clinique Charcot
Sainte Foy Les Lyon, France, 69110
Centre Hospitalier de Semur en Auxois
Semur en Auxois, France, 21140
Centre Paul Strauss
Strasbourg, France, 67065
Hopital Universitaire Hautepierre
Strasbourg, France, 67098
Centre Hospitalier de Tarbes
Tarbes, France, 65013
Institut Claudius Regaud
Toulouse, France, 31052
CHU de Tours
Tours, France, 37044
Centre Alexis Vautrin
Vandoeuvre-les-Nancy, France, 54511
Institut Gustave Roussy
Villejuif, France, F-94805
Sponsors and Collaborators
Study Chair: Thierry Conroy, MD Centre Alexis Vautrin

Publications of Results:
Ychou M, Desseigne F, Guimbaud R, et al.: Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): first results of the ACCORD 11 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-4516, 2007.

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00112658     History of Changes
Other Study ID Numbers: CDR0000430100
First Posted: June 3, 2005    Key Record Dates
Last Update Posted: May 20, 2011
Last Verified: December 2006

Keywords provided by National Cancer Institute (NCI):
adenocarcinoma of the pancreas
stage IV pancreatic cancer

Additional relevant MeSH terms:
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Phytogenic
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Protective Agents